公司资料
Monopar 股价、新闻与催化剂
- 股票代码:
- MNPR
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
102.70 USD (+1.23%)
收盘价
最后更新: 2026年9月17日
410M USD
市值
股价为何变动
截至 2026年9月17日，MNPR 上涨 1.23%，收于 $102.70。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Monopar Therapeutics is a biotechnology company focused on oncology and rare disease, with a history of targeting difficult indications. Its narrative is built around using a concentrated pipeline to create value in high-unmet-need settings.
所在地与行业分类
Monopar is headquartered in the United States and listed on NASDAQ. It sits in small-cap specialty biopharma.
商业模式特征
The company depends on clinical progress, strategic prioritization, and capital management across a narrow program set. Investors typically watch proof-of-concept data and financing runway.
生物医药行业定位
Monopar occupies a catalyst-sensitive niche within biotech. The stock is driven by whether its focused development approach can produce clear differentiated value.
未来催化剂
- What matters most for Monopar from here is ALXN1840 and tiomolibdate choline. That matters because the company is now talking about NDA Submission on Track for Mid-2026 In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) at.... That is the piece most likely to shape sentiment in the near term.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。